Oestrogen Receptor in Human Breast Cancer Tissue and Response to Endocrine Therapy

Engelsman, E; Persijn, J.-P.; Korsten, C. B.; Cleton, F. J.

doi:10.1136/bmj.2.5869.750

Cited by 75 publications

(14 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This EBP exhibited properties similar to EBP found in experimentally induced breast cancer with DM BA in rats [21]. Preliminary reports indicate a greater rate of regressions in patients with significant amounts of EBP [7,13,17,19]. This finding may provide the major achievement made to the present to predict responses to an endocrine treatment.…”

Section: Discussionmentioning

confidence: 52%

See 1 more Smart Citation

<i>In vivo </i>Blockade of the Estradiol-Binding-Protein (EBP) by Clomiphene Citrate in Human Breast Cancer

Garola¹,

Levy²,

Vegh³

et al. 1974

Oncology

View full text Add to dashboard Cite

A 60-year-old woman with disseminated breast cancer was studied for the presence of estradiol-binding-protein (EBP) before and while on treatment with 200 mg daily of clomiphene citrate. A biopsy from one of her multiple subcutaneous nodules taken prior to treatment showed 86 fmol estradiol binding sites/mg cytoplasmic protein with a dissociation constant of the estradiol-EBP interaction of 2.8 x 10^––¹⁰m. A second biopsy taken at day 26 of treatment with clomiphene citrate showed complete inhibition of labelled estradiol (3 H-E₂) uptake by the cytosol protein associated with striking clinical and humoral improvement. This is the first evidence, as far as we know, of human in vivo inhibition of 3 H-E₂ uptake by EBP by means of an antiestrogen compound. The role of EBP quantitation in predicting the response to endocrine treatment as well as the potential therapeutic value of antiestrogens are discussed.

show abstract

Section: Discussionmentioning

confidence: 52%

“…The efforts of many investigators has been directed to correlate the presence of EBP in human breast cancer with the response to an endocrine treatment and preliminary reports indicate significant tumor regression in patients who exhibited EBP [7,13,17,19].…”

Section: Introductionmentioning

confidence: 99%

<i>In vivo </i>Blockade of the Estradiol-Binding-Protein (EBP) by Clomiphene Citrate in Human Breast Cancer

Garola¹,

Levy²,

Vegh³

et al. 1974

Oncology

View full text Add to dashboard Cite

show abstract

“…The reports by Jensen et al (1973) andEngelsman et al (1973) referred to above, suggest a correlation between the content of oestradiol receptor protein and hormone dependence in human mammary tumours.…”

Section: Resultsmentioning

confidence: 83%

“…Determination of the content of oestradiol receptors in the tumour has proved to be valuable in predicting the outcome ofendocrine ablation in mammary cancer patients , and there are indications that there is a correlation between the response to oestrogen or anti-oestrogen therapy and the content of receptor protein in the tumour (Engelsman et al, 1973). Estimates of the amounts of various proteins known to be subject to hormonal regulation are conceivably also of value in predicting the hormone dependence of a given tumour.…”

mentioning

confidence: 99%

High affinity oestradiol receptors and the activity of glucose-6-phosphate dehydrogenase and lactose synthetase in mammary carcinomata of postmenopausal women

Daehnfeldt¹,

Schülein²

1975

Br J Cancer

View full text Add to dashboard Cite

Summary.-The determination of hormone inducible proteins in endocrine tumours may yield information about the presence of hormone dependent tumour cells. We have estimated the high affinity oestradiol binding capacity in primary mammary carcinomata of 57 postmenopausal patients. Glucose-6-phosphate dehydrogenase and lactose synthetase are known from animal experiments to be hormone inducible. Therefore, in biopsies of sufficient size the activity of glucose-6-phosphate dehydrogenase (47 patients) and lactose synthetase (23 patients) was also studied. It was found that biopsies with high binding capacity also showed high activities of glucose -6-phosphate dehydrogenase and lactose synthetase A protein (galactosyl transferase). No lactose synthetase B protein (a-lactalbumin) has been discovered in the tumours. The present observations may be considered suggestive evidence of a relationship between high oestradiol binding capacity and high activities of the two enzymes on the one hand and hormone dependence of the tumour on the other. However, further clinical studies are required before final conclusions in this respect can be drawn.

show abstract

“…The fact that estrogen receptor-positive and -negative tumors can co-exist in the same patients, and that metastatic tumors are less likely to be estrogen receptor positive than primary tumors, especially following radiation therapy or chemotherapy, suggests to Leclercq et al [64] and Savlov et al [85] [34], McGuire and associates [71] found approximately 50 to 70% of all patients will respond to endocrine ablation. Engelsman [37] and Moseley [75] [53,54] have discovered progesterone receptors in 30 to 50% of all breast cancers tested, and patients with both estrogen and progesterone receptor-positive tumors will most uniformly benefit from endocrine ablation. The Degenshein group [32] went on to find that approximately one-third of the number of patients, however, will have one receptor or the other, and further confirmation of a hormone-insensitive tumor should be obtained before withholding endocrine therapy.…”

Section: Discussionmentioning

confidence: 98%

The importance of treatment sequence in advanced and metastatic carcinoma of the breast

Awrich

Peetz

Moseley

et al. 1982

Journal of Surgical Oncology

View full text Add to dashboard Cite

From 1965 to the present, 287 patients with advanced and metastatic carcinoma of the breast have been treated according to a uniform philosophy of sequential therapy. Surgical castration was the initial procedure for premenopausal women and for postmenopausal women with clinical or laboratory evidence of endocrine responsive tumors. Tumor progression following castration was treated with major endocrine ablation, either adrenalectomy or hypophysectomy. Patients who relapsed following major ablation were treated with antiestrogen therapy as it became available. Nonresponders to major ablation and patients relapsing after antiestrogen therapy were treated with combination chemotherapy including cytoxan, methotrexate, 5-fluorouracil, and vincristine followed by adriamycin alone or in combination. Progression following chemotherapy was treated with additive hormonal therapy. Radiation therapy was used throughout for the control of localized disease, usually following complete hormonal ablation, except in cases of brain and spinal metastatic disease. The median survival for the entire group was 40.5 months from the onset of metastatic disease. Patients who responded to both oophorectomy and major ablation had a median survival of 61 months, which compares favorably to survival of 14 to 22 months reported in major combination chemotherapy trials. Survival following this method of sequential therapy is superior to other plans of management.

show abstract

Oestrogen Receptor in Human Breast Cancer Tissue and Response to Endocrine Therapy

Cited by 75 publications

References 5 publications

<i>In vivo </i>Blockade of the Estradiol-Binding-Protein (EBP) by Clomiphene Citrate in Human Breast Cancer

<i>In vivo </i>Blockade of the Estradiol-Binding-Protein (EBP) by Clomiphene Citrate in Human Breast Cancer

High affinity oestradiol receptors and the activity of glucose-6-phosphate dehydrogenase and lactose synthetase in mammary carcinomata of postmenopausal women

The importance of treatment sequence in advanced and metastatic carcinoma of the breast

Contact Info

Product

Resources

About